Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 25
Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 26
Aug 27, 2023, 15:01
Andrius Žučenka: Excited that our center is currently enrolling R/R AML pts in 2 clinical trials.
Andrius Žučenka, hematologist, researcher, lecturer and PhD candidate at Vilnius University Hospital Santaros Klinikos, made the following post on Twitter:
“Excited that our center is currently enrolling R/R AML pts in 2 clinical trials:
-Revumenib (Menin inhibitor) for KMT2Ar or NPM1m (+ALL,MPAL). AUGMENT-101, Phase 2
-MP0533 (AntiCD33+CD123+CD70 T-cell-engager DARPin), mutation agnostic. MP0533-CP101, Phase 1”
Source: Andrius Žučenka / Twitter